Since the Patient The Hidden $11 Billion Economy Behind One of the Decade’s Most Explosive Headlines

#1 Best-selling Finance Author and Entrepreneur Robert Kiyosaki reveals what could be the Main Street investor’s most profitable way to take advantage of a “hidden economy

9 Reasons Why One Under-the-Radar Company and Its Breakthrough Technology May Be the Most Important Biotech Investors Have Never Heard Of

By Robert Kiyosaki | 

Thursday, May 22, 2026 10:00 A.M. CDT · 10 min read

Disseminated on Behalf of Conexeu Sciences Inc. 

Wall Street has spent the better part of three years fixating on the GLP-1 obesity drug revolution.

For good reason: Eli Lilly’s tirzepatide franchise alone generated $36.5 billion in revenue last year, making it the world’s best-selling drug.[1]

And investors who got in on the GLP-1 trend early saw some stunning growth.

From July 2023 to July 2024, Eli Lilly’s stock price absolutely exploded as FDA approvals hit and its blockbuster weight-loss drug hit commercialization.

Over that twelve-month window, shares ripped roughly 98.2% as the market realized GLP‑1 demand would overwhelm supply for years.[2]

Eli Lilly share price moved from $461.42 on July 3, 2023 to $914.37 on July 1, 2024 … a massive ~98.2% move.

Not to be outdone, Novo Nordisk — whose semaglutide products Ozempic and Wegovy have become household names — skyrocketed as much as 82.5% as in the same period.[3]

Novo Nordisk share price jumped from July 3, 2023 to July 1, 2024, delivering 82.5% growth as Ozempic and Wegovy cemented its GLP‑1 frontrunner status.[3]

Chasing the success of these pharma giants, approximately 170 weight-loss drugs are currently in development, chasing what BCC Research projects will be a $268.4 billion global GLP-1 market by 2030.[4][5]

But there is a second economy forming behind this pharmaceutical juggernaut — one that almost no investor in public or private markets is talking about.

When tens of millions of patients lose weight rapidly on GLP-1 medications, they don’t just lose fat.

They develop what the media has dubbed “Ozempic Face” — losing facial volume, tissue structure, and skin quality alongside their slimming waist — and this second-order market could soon be worth billions.  

A Breakout Trend Exceeding 5,000% Growth[6]

The “Ozempic Face” surge is driven by GLP-1 patients who look, by some clinical estimates, up to five years older than their peers who haven’t lost weight.

This “rapid onset aging” following a GLP-1 weight loss regimen has become a term that has seen search growth exceeding 5,000% on Google, achieving “breakout” status in Google Trends.[6]

This phenomenon is creating an entirely new downstream medical economy — one that Boston Consulting Group estimates will grow from $700 million to $2 billion in provider revenue within five years. [7]

It’s this shocking reality that led me to direct my team to find a little-known company positioned to capitalize on this trend …

… and what my research uncovered shocked me.

The Kiyosaki Playbook … Revealed

For more than 50 years, I’ve watched ordinary investors chase headlines while the wealthy quietly positioned themselves behind the scenes of the real opportunity.

That lesson changed my life.

It’s the reason Rich Dad Poor Dad became the bestselling personal finance book in history, selling more than 40 million copies worldwide and reaching readers in over 100 countries.

I didn’t build my reputation by repeating Wall Street talking points.

I built it by identifying massive economic shifts before the crowd understood what was happening.

Years before the 2008 financial crisis, I warned Americans that the housing market was sitting on a time bomb.

I spent decades teaching people why hard assets like oil, real estate, gold, and energy infrastructure create lasting wealth while paper assets can evaporate overnight.

And over and over again, I’ve seen the same pattern repeat itself.

Best-Selling Personal Finance Author and Self-Made Millionaire Robert Kiyosaki

The biggest fortunes are rarely made in the obvious company everyone is talking about.

They’re made in the businesses feeding the explosion behind the scenes.

During the gold rush, it was the merchants selling picks and shovels.

During the oil boom, it was the pipeline operators collecting cash flow whether oil prices rose or fell.

And today, I believe the GLP-1 explosion could be creating the exact same kind of asymmetric opportunity.

Because when tens of millions of people rapidly lose weight and suddenly look older in the mirror, they don’t simply ignore the problem.

They look for solutions.

And where desperate consumers rush for solutions, massive rivers of money usually follow.

That is exactly why I told my research team to dig deeper into this emerging “Ozempic Face” economy.

What they uncovered could represent one of the most overlooked medical aesthetic opportunities I’ve seen in years.

Kiyosaki: I Have Never Seen a Market Growing This Quickly

Aesthetics has been a major industry for decades, but this new GLP-1 adjacent market could be the biggest market shift in years.

You see, global aesthetic injectables alone are already an approximately $11 billion market[32], with Botox‑type drugs representing about a $9 billion global business and medical aesthetics as a whole projected to nearly triple to almost $89.6 billion between now and 2034.[8]

But here’s the problem …

This multi-billion-dollar industry isn’t equipped to handle “Ozempic Face” and hasn’t seen genuine innovation in decades.

And its flagship product — Botox — hasn’t changed formulation in decades, despite generating tens of billions of dollars in revenue over its lifetime.

And the real killer is this:

“The legacy products currently available to address this “Ozempic Face” crisis are not only not designed for it … their solutions are woefully inadequate to actually fix the problem.”

Hyaluronic acid fillers are 20-year-old temporary volumizers.[9]

Biostimulators trigger inflammatory responses rather than true regeneration.

Neither rebuilds tissue. Neither restores what was lost.

What’s needed is a new solution … one that not only adds back lost volume, but actually gives the body what it needs to rebuild real tissue in place …

… a solution with low inflammation, natural ingredients, and the potential for long‑lasting structural repair instead of yet another short‑term cosmetic patch.

And, if you’ll bear with me for a few minutes, I’ll tell you about a company I found that does exactly that.  

Before I introduce you to that company, though, I want you to understand why this market is exploding …

.. why Big Pharma is spending billions to gobble up proven IP …

… and why this company’s innovation might be the most perfectly timed product coming to market since the iPhone.

The Biggest Drug Market Expansion in a Generation

The GLP-1 revolution is a structural transformation of global healthcare.

As I mentioned, Eli Lilly’s stock saw explosive growth in 2023-2024 following FDA approval of its blockbuster drugs.

In its most recent filing, the company reported full-year 2025 revenues of $65.2 billion — a 45% increase over 2024, driven almost entirely by the explosive growth of its tirzepatide franchise.

Mounjaro, its diabetes formulation, generated approximately $23 billion in 2025.

Zepbound, its obesity formulation, contributed $13.5 billion.

Combined, these two products accounted for 56% of Lilly’s total annual revenue — and sales nearly doubled year-over-year.[10]

But this is not a one-company story.

Pfizer beat Q4 2025 estimates with $17.6 billion in quarterly revenue and is investing aggressively in its own monthly GLP-1 obesity drug, with ten Phase 3 trials planned for 2026.[11]

Novo Nordisk’s drug growth shows just how fast this market is moving.

In its 2025 annual report, the company notes that its obesity drugs generated roughly $12.5 billion dollars in sales, up 26% from the year before.

The overall branded GLP‑1 obesity market more than doubled in volume, and Novo Nordisk held about 60% of that market, even as new competitors like Eli LIlly’s tirzepatide gained ground in global prescription data.[12]

BCC Research values the global GLP-1 analogues market at $54.8 billion in 2024 and projects it will reach $268.4 billion by 2030, growing at a compound annual growth rate of 30.6%.[5]

GLP-1 Adoption Has Reached Population Scale

All of this to say, GLP-1s are no longer a niche pharmaceutical category.

According to KFF Health Tracking Poll data, approximately 12% of U.S. adults — representing roughly 32 million people — report having used a GLP-1 receptor agonist at some point, with about 6% reporting current use.[13]

GLP-1 prescriptions have increased approximately 500% over five years.[14]

The implications of this adoption curve are difficult to overstate.

Millions of patients are losing weight rapidly — up to 10% to 20% or more of their body weight on these medications.

This creates a growing population of patients whose rapid weight loss produces downstream consequences that the current medical aesthetics toolkit was never designed to address.

The Hidden “Second Economy” Nobody Is Pricing In

You only need to look at the charts to see that Wall Street understands the GLP-1 obesity drug story.

What Wall Street does not yet understand — and what represents the real opportunity — is the hidden economy forming behind it.

When patients lose significant weight rapidly via GLP-1 medications, they don’t simply become thinner.

They experience deflation and loss of facial fat pads, structural soft tissue changes, skin laxity, and degradation of collagen and elastin quality.

In other words, they look older, faster.

And, as I mentioned, this condition is so widespread it already has a name: Ozempic Face.

Moms, dads, grandmas, athletes and celebrities are aging seemingly overnight as GLP-1s remove fat from their face at an alarming rate.

This crisis no one saw coming is sending GLP-1 users rushing to medical aesthetics to restore their youthful beauty…

But the “best in class” aesthetics technology available today is decades old, and, at best, can only offer a temporary fix. 

I have told my subscribers that this is a critical distinction for investors —  this represents entirely new demand entering the medical aesthetics market.

McKinsey’s survey of 174 U.S. aesthetic providers conducted in late 2024 found that 63% of GLP-1 patients seeking facial aesthetic products or procedures were not active users of medical aesthetics services.[15]

Roughly half had never even considered aesthetics prior to their weight loss.

And Galderma has reported that 53% of U.S. aesthetic clinics anticipate that medication-driven weight loss will drive increased demand for treatments addressing facial changes.[16]

This new demand represents an entirely new consumer class entering medical aesthetics …

… one that requires programmatic, multi-session restoration rather than the occasional wrinkle treatment.

This “New Economy” By the Numbers

And it’s not just me saying this.

Experts across the country are saying that this new consumer market is going to be growing exponentially (and dropping some serious money) over the next few years to deal with the second-order fallout of the GLP-1 revolution.

Boston Consulting Group estimates that clinical provider revenue from treating post-weight-loss aesthetic concerns will grow from approximately $700 million to $2 billion over the next five years — representing $1.3 billion in incremental new revenue to the aesthetics industry. [7]

The American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) has reported a 50% rise in the average number of fat grafting procedures, likely tied to patients addressing post-GLP-1 facial volume loss.[17]

Dr. Atchima Suwanchinda, Vice President of the International Society for Dermatologic Surgery, has stated: “Post-GLP-1 body management is going to emerge as its own category… expanding into regenerative and tissue-health applications as millions of GLP-1 patients seek solutions for laxity rather than volume loss”.[18]

Dr. Johnny Franco, a top plastic surgeon in Austin, Texas, captured the clinical reality: “The biggest shift we’re seeing, and it’s still accelerating, is the ripple effect of GLP-1 drugs throughout aesthetics. Millions of people are starting or cycling through these medications this year, and the downstream impact is enormous”.

In fact, one in four surgeons surveyed expect GLP-1s to drive higher demand for non-surgical treatments including fillers and skin tightening.[19]

But there’s a massive problem.

Legacy Products Are Failing to Evolve With the Market

The medical aesthetics market, despite being valued at $28.49 billion in 2025 and projected to reach $89.59 billion by 2034, is running on 20-year-old technology.

In fact, some of these technologies are older than the people using them!

Restylane, an HA filler, launched in Europe in 1996 and received FDA approval in the United States in 2003.[20]

It is now celebrating 30 years on the market.

Juvederm received its original FDA approval on June 2, 2006.[21]

By the time you read this, it will officially be two decades old.

And in all that time, the fundamental mechanism of HA fillers has remained essentially unchanged.

Why HA Fillers Fail at the “Ozempic Face” Problem

The FDA’s own description of hyaluronic acid fillers makes the limitation explicit:

“HA is a sugar found in skin. When injected, HA combines with water and swells, creating a smoothing/filling effect. HA is chemically modified (crosslinked) to last longer and typically lasts 6–12 months”[22]

This is a temporary space-filler. It is not a regenerative tissue-replacement therapy.

For post-GLP-1 patients who have experienced large-scale tissue loss — multi-area deficits including volume depletion, skin laxity, and structural quality degradation — the limitations become severe:

• Volume restrictions: Product labeling for products like Juvederm Ultra XC note that “the safety of injecting greater amounts has not been established” and provide annual volume limits (e.g., 20 mL per 60 kg body mass per year).
• Duration limitations: HA fillers typically last 6–12 months, requiring ongoing repeat treatments that become economically burdensome for large-area restoration.
• Historical failures at larger volumes: When the industry previously attempted to scale HA gels to larger-volume indications — such as Macrolane for breast augmentation — the approach was withdrawn due to safety concerns including obscuring mammography and potentially delaying breast cancer diagnosis.

Biostimulators: Better, but Still Not Regeneration

Current biostimulators — products like Sculptra, Radiesse , and Bellafill — represent an advance over pure HA fillers in that they trigger new collagen production.

However, their mechanism relies on creating a controlled inflammatory response — essentially, the body’s fibroblasts rush to “repair” what they perceive as micro-invasion from foreign particles.

This is fundamentally different from true tissue regeneration.

Biostimulators work by provoking a reaction, not by providing the biological architecture that native tissue requires to rebuild itself.

It’s an inflammatory response, not a true fix, because the resulting collagen formation is a response to perceived injury rather than regeneration.

Neuromodulators Are a $12.8 Billion “One Trick Pony”

On the neuromodulator side, the tools haven’t really changed — only the branding has.

The best‑known name, Botox, is still approved simply to “temporarily improve” the appearance of frown lines by weakening the underlying muscles.

Botulinum toxin type A works by temporarily paralyzing the injected muscle and softens movement‑based wrinkles.

The effect typically starts within a few days and lasts about three to four months before nerve terminals recover and movement returns.

Every major competitor — Dysport (abobotulinumtoxinA), Xeomin (incobotulinumtoxinA), Jeuveau, and Daxxify (daxibotulinumtoxinA‑lanm) — uses the same basic active ingredient: botulinum toxin type A.

They differ in formulation, diffusion, onset, and duration, but they all do the same thing at a cellular level: temporarily relax muscles by interrupting nerve signaling.

None of them rebuilds lost fat pads, or restores collagen architecture; they fill gaps, not structure.

And that’s the core problem in the GLP‑1 era.

Neuromodulators can still erase frown lines and crow’s‑feet, and they remain a massive business, but they do nothing for the hollow cheeks, loose skin, and collapsing support structures that come with large, rapid weight loss.

Despite this, Fortune Business Insights says the market size will be an estimated $12.8 billion in 2026.[23]

The market for neuromodulators like Botox is approximately $12 billion a year and growing rapidly Source: https://www.fortunebusinessinsights.com/industry-reports/botulinum-toxin-market-100996

People are obviously willing to shell out serious money to feel beautiful … even if it’s only temporarily.

To me, the takeaway is clear: GLP-1s are expanding the aesthetic market, but they are exposing a massive product-market mismatch.

The unmet need is not merely wrinkle filling.

It is higher-magnitude tissue and skin restoration after rapid weight loss.

A New Category Is Emerging … and Early Investors Could Find Themselves Positioned for Windfall Profits

I won’t go too deep into the science, but suffice it to say the solution is well understood in its fundamentals.

For the body to regenerate functional tissue — not scar tissue, not inflammatory deposits, but actual organized tissue that behaves like the original — three elements are required:

1. Cells — the biological workers that construct new tissue
2. Signals — the biochemical cues that tell cells what to build and where
3. Scaffold — the structural framework that guides organized tissue formation

In a bad injury like a burn – the scaffold has literally been destroyed …and it NEEDS to be replaced.

Legacy aesthetic products address none of these requirements in an integrated manner. 

HA fillers provide no scaffold and no regenerative signals.

Biostimulators provide inflammatory signals but no scaffold.

The opportunity, then, is clear: a technology platform that can provide the body a path to natural tissue regeneration will have a massive advantage in a market desperate for real, longer-term solutions …

… Which is exactly what my research team has found.

9 Reasons Why Conexeu Sciences (NASDAQ: CNXU) Has a Powerful Advantage in a $11 Billion Market

Conexeu Sciences (NASDAQ: CNXU) has a breakthrough product that is designed to do something today’s fillers and wound products simply can’t.

Its flagship product, CXUTM starts as a liquid that injects easily, flows into complex defects, and then gently gels at body temperature in about ten minutes to form a stable, collagen‑based scaffold.

This “Ten Minute Tissue” is built to act like real extracellular matrix, giving cells the structural support and biological signals they need for organized healing instead of random scar tissue.

Ten Minute Tissue is biomimetic, meaning its architecture is designed to mimic the scaffold material the skin itself produces, providing instant volume and inviting the body to grow real tissue into it native ECM and guide cells toward true tissue repair.

It’s temperature‑responsive, so it stays fluid while you place it, then gels in‑situ at body temperature to match irregular wound beds and tissue gaps.

It’s engineered for a low inflammatory response, unlike biostimulators that work by provoking inflammation to get results.

And, unlike other fillers on the market, once it is in place, it is used by the body to and disappears over time … meaning this “Ten Minute Tissue” product has a unique and powerful differentiator that would be very difficult for other companies to replicate.

ITen Minute Tissue is also built as a platform, not a single‑use product.

It can work as an injectable regenerative device and as a printable ECM bioink for 3D bioprinting applications.

The material comes as a shelf‑stable, lyophilized powder that doesn’t need refrigeration, can use different collagen sources, rehydrates quickly in saline or plasma, and goes through a standard syringe.

In preclinical, head‑to‑head testing against somewhat similar products, Ten Minute TissueTM closed the wounds nearly three times faster at multiple time points, achieving by day 21.[24]

Reason 1: This Is a Potentially Category Defining Technology

The strongest framing for Conexeu’s opportunity is not as a filler company, not as a cosmetic company, and not as an obesity drug story. It is this: a platform technology entering a market vacuum created by GLP-1 demand.

Conexeu occupies the “sweet spot” between:

• Temporary HA fillers (which fill space but don’t regenerate)
• Biostimulators (which provoke inflammation but don’t scaffold)
• Invasive surgery/fat grafting (which transfers tissue but requires an operating room)

No currently marketed product offers an office-based, injectable regenerative tissue-replacement approach with the potential for durable structural improvement and true tissue-quality enhancement.

This is the category Conexeu is attempting to define and own globally …

… and there’s a precedent of companies that become “category defining” creating generational wealth for investors.

How a Niche Tool Becomes a Billion-Dollar Category

To understand the potential magnitude of what Conexeu is chasing, investors need only look at the history of a familiar name we’ve already discussed:

Botulinum toxin — better known as Botox.

Botox was originally FDA-approved in 1989 for two eye muscle disorders: strabismus (crossed eyes) and blepharospasm (uncontrolled blinking).

It was a niche pharmaceutical tool serving a small clinical population. No one at the time imagined it would become the foundation of an entirely new category of medicine.

In 2002, the FDA approved Botox Cosmetic for temporary improvement of moderate to severe frown lines. The brand exploded.

By 2024, Botox Cosmetic was generating $2.72 billion in global net revenue, while Botox Therapeutic brought in another $3.28 billion — a combined total exceeding $6 billion annually from a single platform technology.[25]

AbbVie’s entire Aesthetics portfolio, anchored by Botox Cosmetic and Juvederm, generated $5.18 billion in 2024.[26]

Botox holds approximately 60% of the U.S. neuromodulator market despite increasing competition from products like Dysport, Xeomin, Daxxify, and Jeuveau.[27]

It has become so synonymous with its category that many consumers use the brand name generically, the way people say “Kleenex” instead of “tissue”.

The Parallels for Conexeu’s “Ten Minute Tissue”

The Botox precedent is instructive for three reasons:

First, it demonstrates that a single platform technology, when it creates a genuinely new category, can achieve market dominance that persists for decades.

Second, it shows that the aesthetic application of a medical technology can exceed its original therapeutic purpose in commercial value.

Botox began as a treatment for a medical condition. Its aesthetic franchise became equally large.

Third, and most importantly for the Conexeu thesis, it proves that the market rewards category creation over incremental innovation.

Botox didn’t improve existing wrinkle treatments — it created an entirely new approach.

The question facing investors now is whether regenerative scaffolding could represent the next such category shift in aesthetics — a transition from temporary volumization and muscle paralysis to actual tissue regeneration.

If and when Ten Minute Tissue technology gets FDA clearance, Conexeu could be through the first stage,  will be ready for commercialization, with a new FDA-approved device, and move it towards creating a filler category.

And in aesthetics, category creators have the potential to capture astounding value.

Just look at Botox — as we’ve discussed, its fundamental mechanism has not changed in over 20 years, yet it still commands a $6 billion annual business.

Reason 2: An “Overnight Success” Twelve Years in the Making

A common mistake in biotech investing is conflating all early-stage companies. Some are concept-stage — little more than a PowerPoint and a hypothesis.

Others have been years in development, quietly building a scientific foundation while waiting for the right market moment.

Conexeu falls squarely in the latter category.

The Ten Minute Tissue platform emerged from more than a decade of research at a leading Canadian university, with Dr. Claudia Chavez-Munoz — a surgeon-scientist recognized internationally for her contributions to burn care, wound healing, and tissue regeneration — leading the foundational science.

Dr. Chavez-Munoz serves as Adjunct Professor in the Faculty of Medicine at the University of British Columbia, where she has mentored graduate trainees and contributes to the Undergraduate MD Program through lectures in regenerative biology and surgical innovation.

Her academic research continues to focus on extracellular matrix-based therapies — the very science that underpins Conexeu’s commercial platform.

The company’s intellectual property position reflects this depth.

Ten Minute Tissue technology is protected by patents secured in the United States, European Union, Japan, and Australia, with a Canadian patent pending.

Critically, these patents are owned outright — the company pays no licenses or royalties to external parties.

The preclinical data supports the platform’s biological claims.

In head-to-head studies, Ten Minute Tissue demonstrated wound closure rates nearly three times faster than Integra’s Flowable Wound Matrix at multiple time points.

Supported by multiple peer-reviewed publications, the technology has been validated across wound care, aesthetic, and tissue engineering applications.

The 3D Bioprinting Breakthrough

In November 2025, Conexeu announced a milestone that extends the technology’s addressable market significantly: the successful creation of the first-ever 3D-printed tissue structures composed entirely of its proprietary, functional extracellular matrix.

Using the Ten Minute Tissue platform as a bioink, the company fabricated bovine-derived, collagen-based scaffolds that mimic real tissue characteristics.

As Dr. Chavez-Munoz explained: “By showing that CXU can print tissue structures, we are opening the door to truly personalized implants and grafts. If cleared by the FDA, this will place CXU at the forefront of all bioinks, being the first collagen-based extracellular matrix medical grade in the market”.

This advancement opens three additional market avenues: personalized implants and grafts (craniofacial, breast, periodontal, and soft-tissue reconstruction, printed to match the patient), vascular-supportive microenvironments for keeping cells alive in regenerated tissue, and biofabrication applications for future clinical use.

Reason 3: The Company Is Attracting Major Attention Accolades as Are Starting to Pile Up

Conexeu isn’t just another med‑tech startup — it’s already getting noticed by the people who matter.

In early 2026, Life Sciences Review named Conexeu a Top Regenerative Medicine Solution Provider, calling out the company for doing something different in a crowded market: instead of just “patching or protecting,” it’s built to accelerate the body’s own regeneration process.

The financial press is starting to echo that story.

A 2025 news release picked up by Yahoo Finance framed Conexeu’s CXU platform as a “major breakthrough” in personalized human tissue creation, highlighting successful 3D‑printed, collagen‑based scaffolds that behave more like real tissue than traditional fillers or patches.

Investor response has followed – Conexeu has raised significant capital to fund its business needs with overwhelmingly strong investor demand.

In fact, in October 2025, the company closed a $5 million Regulation Crowdfunding financing, securing commitments in excess of $5 million in less than two weeks.

Reason 4: Potentially Faster, Cheaper, and Lower Risk

In my opinion, one of the most under-appreciated aspects of the Conexeu investment thesis is the regulatory pathway the company is actively pursuing.

Unlike GLP-1 drugs … which require a decade or more of clinical trials, hundreds of millions of dollars in development costs, and carry substantial risk of Phase 3 failure …

…Conexeu’s Ten Minute Tissue technology is being developed as a medical device with a path toward FDA clearance through mechanisms such as the 510(k) pathway.

While the 510(k) pathway isn’t guaranteed and the FDA might require a more rigorous approach, the contrast between drug and device regulatory pathways is dramatic:

Different FDA approval pathways can make a dramatic difference in a therapy’s time to market.[28][29][30][31]

The FDA’s target review time for 510(k) submissions is approximately 90 days, with a first-cycle clearance rate of approximately 95%.

Compare this to the pathway for high-risk devices (180+ day review, $540,783 standard user fee) or the new drug pathway, where Phase III clinical trials alone can cost $25 million to $350 million or more.

And the full development cost averages $1 billion to $2 billion per approved drug![28][29][30][31]

This smart approach to FDA approvals directly translates into several positive outcomes:

• Streamlined process potentially mean lower capital burn: The company does not need to raise hundreds of millions of dollars to fund Phase I–III clinical trials. This capital efficiency is orders of magnitude better than drug development economics.
• Potentially lower risk than a New Drug pathway: The device pathway, while not without risk, does not carry the same potential downside of catastrophic Phase 3 failure that can wipe out billions in pharmaceutical company value overnight.
• Faster time to market potentially means longer profitability: A 510(k) clearance pathway can take as few as 4–12 months from submission preparation through FDA review, compared to 10–15 years for a new drug. This means it could potentially be make money sooner, with a longer patent life.

In other words, Conexeu is aiming for a fast, capital‑efficient path instead of a decade‑long drug slog.  

It’s pursuing a regulatory route closer to a “consumer equivalency” filing — which means far less capital than a full drug program, no 10‑year wait, and no need to fund $100‑million‑plus Phase I–III trials just to get to market.

Reason 5: One Platform, Multiple Billion-Dollar Verticals

The Ten Minute Tissue platform is not a single‑product bet – it is a collagen‑based extracellular matrix scaffold designed from day one to plug into multiple, already‑large markets with a combined addressable opportunity of roughly $20.8 billion.[32][33][34][35][36]

These include …

Medical Aesthetics (~$11 billion)

Conexeu slots Ten Minute Tissue directly into the global aesthetic injectables market, which the deck sizes at approximately $11 billion.

In a category still running on decades‑old HA fillers and biostimulators, Conexeu’s goal is not to be “another filler,” but to define an entirely new category in aesthetics.

Wound Care (~$2.6 billion)

The same core technology is also being advanced as a liquid skin substitute in wound care, a market worth about $2.6 billion.

Here, Ten Minute Tissue is positioned to do what sheets, grafts and flowables struggle with: flow into deep, tunneling, and irregular wounds, gel in about ten minutes at body temperature, and provide a conforming scaffold that supports tissue integration and faster closure in preclinical head‑to‑head data.

In fact, Ten Minute Tissue was originally invented for this space — to help burn victims and wounded warriors with recovery.

Dental / Soft‑Tissue Gums (~$4.2 billion)

Dentistry is another massive field generating about $4.2 billion annually that Coenxeu’s breakthrough technology has an opportunity to totally upend.

Collagen‑based matrices and membranes are already standard tools in guided bone and soft‑tissue regeneration, and Ten Minute Tissue aims to dominate the category with its next‑generation collagen scaffold built for precise placement and integration in periodontal procedures.

Veterinary Wound Care (~$1.4 billion)

The company didn’t forget about all the puppies and kitties in the massively growing pet market.

Americans are spending more than ever on their pets, and because Ten Minute Tissue is collagen‑agnostic, it easily extends into veterinary medicine.

This is an additional revenue vertical where animals — like humans — need advanced scaffolds for wounds, surgical sites, and reconstructive procedures, but today face many of the same limitations seen in human wound care.

3D Bioprinting Inks & Tissue Scaffolds (~$1.6 billion)

Finally — and potentially most astonishingly — Conexeu has already demonstrated that Ten Minute Tissue can function as a printable, medical‑grade bioink, which anchors its presence in 3D bioprinting inks and tissue scaffolds.

In plain terms, this could mean that a breast cancer patient could have the exact likeness of her natural breasts implanted following a mastectomy.

And, once the implant is in place, her own tissue would regenerate using the scaffolding as structure.

This, to me, is absolutely astonishing, and I can see massive growth potential even though the field is currently in its infancy.

It’s estimated that this is an estimated market of $1.6 billion but I could easily see it going higher as the technology reaches mass market awareness.

And this is the long-term upside: the same platform that starts as a wound‑care and aesthetics workhorse can also power personalized implants and next‑gen tissue‑engineering applications.

Put together, these five verticals – medical aesthetics (~$11B), wound care (~$2.6B), dental/soft‑tissue gums (~$4.2B), veterinary wound care (~$1.4B), and 3D bioprinting inks/tissue scaffolds (~$1.6B) – are how Conexeu gets to an estimated $20.8 billion total addressable market from a single, patent‑protected collagen scaffold platform.

And that’s the key takeaway here: one technology, multiple billion‑dollar on‑ramps.

“Conexeu’s Ten Minute Tissue platform can address multiple billion-dollar markets from a single IP base.”[32][33][34][35][36]

If Ten Minute Tissue achieves clearance in wound care — its most clinically validated application to date — that success provides immediate revenue, market validation, and a regulatory beachhead from which to expand into aesthetics, dental, and other verticals.

Each subsequent clearance de-risks the platform further while expanding the total addressable market.

By the way, this is the model that built Botox (and Allergan, the company behind it) into a global aesthetics powerhouse.

Botox started with eye conditions, expanded to cosmetic wrinkles, then expanded further to migraines, overactive bladder, and chronic pain.

The Botox platform created the optionality; the market responded.

Reason 6: Biotech Is Surging, Outperforming Even AI Flagship Stocks

After years of underperformance relative to the technology sector, biotech staged a dramatic comeback in 2025.

The SPDR S&P Biotech ETF (XBI), which tracks small- and mid-cap biotech companies, delivered a total return of 35.89% in 2025.[37]

The XBI’s 2025 performance was so strong that biotech, as a sector, outperformed the S&P 500 by a significant margin.[38]

And yet this shift in investor attention has received almost no media coverage.

For a pre-commercial biotech company like Conexeu, the macro implications are potentially huge. For the first time in years, investor appetite for biotech stocks is surging.

Additionally, the IPO and M&A windows are reopening.

More on that momentarily.

Investors are already rewarding biotech platforms that sit at the intersection of clear clinical need and large, obvious markets, and that tailwind directly benefits companies like Conexeu.

Regenerative medicine is one of the hottest corners of that trend, drawing increasing attention from both strategic buyers and growth‑stage capital.

Advances in biomaterials, the global shift toward minimally invasive procedures, aging populations, and a fast‑emerging GLP‑1 aftercare economy are all pulling capital toward true regenerative technologies.

In fact, the AAFPRS reports that 57% of its members now see regenerative medicine as a major innovation area, with PRP and exosome‑based approaches already gaining real traction in clinics.[39]

Conexeu is riding this regenerative wave with a critical edge: its Ten Minute Tissue platform is built to support real tissue regeneration, rather than the inflammatory “controlled injury” mechanism that current biostimulators rely on.

If Conexeu’s preclinical data translate into clinical performance, the company is positioned to define an entirely new regenerative aesthetics category … and there’s nothing Big Pharma likes better than a derisked, ready-to-go platform.

Which brings me to my next reason …

Reason 7: $116 Billion Swapped Hands Last Year When You Weren’t Looking

Big Pharma has a clear pattern: they let small biotechs take the early risk, then write very big checks once the science is proven.

And in the last year, this activity has seen a dramatic uptick.

In 2025 alone, the dollar value of biopharma M&A deals more than doubled year‑over‑year to roughly $116 billion as patent pressure and pipeline gaps pushed giants back into “buy, don’t build” mode.[40]

Pfizer’s $43 billion buyout of antibody‑drug conjugate specialist Seagen shows how far they will go when a platform clearly works and can bolt straight onto an existing oncology franchise.[40]

Pfizer has said Seagen could contribute more than $10 billion in risk‑adjusted revenue by 2030, and the deal instantly doubled Pfizer’s oncology pipeline to about 60 programs.

Novartis is doing the same thing in neuromuscular disease, paying around $12 billion for Avidity Biosciences and its RNA‑based AOC platform rather than trying to invent that delivery technology in‑house.[42]

Merck reached for Verona Pharma in a $10 billion transaction to secure a first‑in‑class COPD drug, again choosing to acquire a de‑risked Phase III asset instead of spending years rebuilding its own respiratory pipeline from scratch.[43]

Sanofi agreed to pay about $2.2 billion for Dynavax to instantly upgrade its adult vaccine portfolio with an approved hepatitis B shot and an in‑house shingles vaccine program.[44]

AbbVie moved to lock up Capstan Therapeutics in a deal worth up to $2.1 billion to grab an in‑vivo cell‑therapy platform and a lead CD19 CAR‑T program for autoimmune disease.[45]

Eli Lilly signed a deal worth up to $1.3 billion for Verve Therapeutics to secure cutting‑edge in‑vivo gene‑editing programs in cardiovascular disease.[46]

2025 was a banner year for biotech M&A.

Across these deals, the message is simple: platform biotechs are being bought, not competed with.

For a platform company like Conexeu, this playbook shows that once you prove real clinical value in a big market, a natural exit path is a premium takeout from a cash‑rich strategic buyer.

Reason 8: Globally Protected Intellectual Property Could Be a Value Driver

In biotechnology, intellectual property is the primary value driver.

A biotech company’s patents determine whether it can exclude competitors from its market, command premium pricing, attract acquirers, and justify its valuation.

Without strong IP, even the most promising technology becomes a commodity.

When I looked into Conexeu’s patent portfolio, I was impressed at what I found.

Its Ten Minute Tissue technology is protected by granted patents in five major jurisdictions: the United States, the European Union, Japan, Australia, and a pending patent in Canada.

These patents are owned outright by the company — Conexeu pays no license fees, royalties, or IP-sharing arrangements to any third party.

This clean IP ownership structure is significant for several reasons:

• No royalty drag: Revenue from commercialized products flows directly to Conexeu without university or licensor take-rates that can range from 3% to 10%+ at other biotech companies.
• Full control over licensing: The company retains the ability to license its technology to partners in specific geographies or applications without requiring third-party consent.
• Acquisition simplicity: Clean IP ownership simplifies the due diligence and transaction process for potential acquirers, who would gain full control of the global patent estate without navigating complex licensing arrangements.

The five jurisdictions where Conexeu holds patent protection — the United States, European Union, Japan, Australia, and Canada (pending) — represent the world’s largest and most developed markets for medical aesthetics, wound care, and dental procedures.[47]

North America alone accounted for 46.09% of the global facial injectables market in 2025.[48]

Europe is the largest global market for aesthetic injectables overall.[49]

Japan is Asia’s most developed aesthetic medicine market.[50]

Australia represents a significant and fast-growing aesthetic consumer market in the Asia-Pacific region.[51]

By securing patent protection across these key markets early, Conexeu has established a defensive moat that any future competitor would need to navigate around — and that any potential acquirer would find highly valuable.

Reason 9: A World-Class Management Team with Multi-Billion-Dollar Wins Under Their Belt

In biotech investing, the quality of the management team is not merely important …

… it is frequently the single most determinative factor in whether a promising technology reaches commercialization.

Conexeu’s leadership team was specifically assembled to avoid this failure mode.

Arriving at Exactly the Right Moment to Take Maximum Advantage of the Megatrend

As I learned about Conexeu’s breakthrough technology … its decade-plus development path … and the “Who’s Who” of leadership that’s been assembled to take this company to the next level …

… one thing that stood out to me was how impeccably timed this technology is.

Consider this.

Some of the greatest investment outcomes in history resulted not from a company having the best technology, but from having the right technology at the right time.

Apple did not invent the smartphone … but it launched the iPhone precisely when mobile internet, touchscreen technology, and consumer appetite for convergent devices aligned.

Tesla did not invent the electric car … but it arrived when battery technology, environmental awareness, and government incentives converged to make EV adoption viable.

Conexeu is arriving at a similar inflection point.

The company’s technology was not developed in response to the GLP-1 boom … it was developed over more than a decade of university research focused on fundamental tissue regeneration science.

But the timing of its commercial emergence coincides almost perfectly with the explosion in demand for post-weight-loss tissue restoration.

Consider the timeline convergence:

• 2012–2023: Ten Minute Tissue technology undergoes more than a decade of university research, preclinical development, and scientific validation.
• 2023: GLP-1 medications begin achieving mass-market adoption; “Ozempic Face” enters public consciousness.
• 2024: 12% of U.S. adults report having used a GLP-1 medication; aesthetic providers begin reporting surge in post-weight-loss patients.
• 2025: Conexeu raises $5 million in under two weeks; recruits former Galderma president as CEO; achieves 3D bioprinting milestone; aesthetic industry begins formally recognizing “post-GLP-1 body management” as a new treatment category.
• 2026: GLP-1 market projected to continue 30.6% CAGR growth through 2030.

This proves to me that Conexeu isn’t a company that has pivoted to chase a trend.

This is a platform technology that was being developed for years, reaching commercial readiness precisely when a massive new market has emerged for exactly the capability it provides.

The “Wealth Window” Is Open … But The Most Compelling Opportunities Might Be Disappearing

I’m sure you don’t need me to tell you this, but market vacuums do not persist indefinitely.

When a multi-billion-dollar unmet need emerges — as the post-GLP-1 aesthetic restoration market represents — competitors will eventually move to fill it.

Large pharmaceutical companies will invest in R&D.

Existing aesthetic companies will attempt to extend their product lines.

New entrants will seek to develop competing technologies.

But — importantly — a true regenerative technology cannot be developed overnight.

And that gives Conexeu Sciences (NASDAQ: CNXU) an immediate edge.

Conexeu’s Ten Minute Tissue reflects more than a decade of foundational science, preclinical validation, and patent development.

Any competitor attempting to replicate this approach from scratch faces years of development time, patent obstacles, and the challenge of building the scientific credibility that Conexeu has already established.

The first-mover advantage in a new category is not merely about being first — it is about being first with a defensible, patent-protected platform.

Conexeu’s combination of validated technology, secured IP, and industry-leading management positions it to potentially capture this advantage in not 1 but 5 multimillion- and even multibillion-dollar markets.